Key result
Targeted therapies such as bosentan significantly reduce pulmonary vascular resistance and increase 6-minute walk distance in patients with Eisenmenger syndrome, warranting further research.
Targeted therapies like bosentan show benefit in advanced PAH-CHD, though robust data guiding optimal timing of interventions remain limited.
No takes yet. Share an insight, caveat, or question.
May support targeted therapies in Eisenmenger syndrome; leaves open optimal timing and durability.
Gatzoulis et al. (2009) conducted a review in Pulmonary arterial hypertension associated with congenital heart disease. Targeted therapies (prostacyclin analogues, phosphodiesterase type-5 inhibitors, bosentan) was evaluated. Targeted therapies such as bosentan significantly reduce pulmonary vascular resistance and increase 6-minute walk distance in patients with Eisenmenger syndrome, warranting further research.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: